Financial Data and Key Metrics Changes - The company has experienced stable and continuous growth in its pharmacological efficacy and modeling segment over the past few years [1] Business Line Data and Key Metrics Changes - The antibody molecules segment, referred to as the "Thousand Trees and Ten Thousand Branches" business, has developed nearly a thousand antibody molecules based on the company's proprietary technology [1] Market Data and Key Metrics Changes - The company aims to establish itself as a global biotechnology firm, leveraging its proprietary technology to expand its market presence [1] Company Strategy and Development Direction - The company is focused on becoming a global biotechnology leader, emphasizing the development of versatile antibodies through its proprietary technology [1] Management Comments on Operating Environment and Future Outlook - Management has highlighted the stable growth in their pharmacological efficacy and modeling segment, indicating a positive outlook for future performance [1] Other Important Information - The company is positioned to leverage its proprietary technology to enhance its product offerings and market reach [1] Q&A Session Summary - No specific questions and answers were provided in the content [1]
百奥赛图(02315) - 2024 Q2 - 业绩电话会